RESCISSION OF DIRECTIVE 2008-003 TREATMENT OF ANTIRETROVIRAL-INDUCED FACIAL LIPOATROPHY IN HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED PATIENTS


2. This VHA Directive is no longer necessary because VHA no longer needs a separate policy allowing subcutaneous injection of permanent or biodegradable filler material as treatment for Antiretroviral-Induced Facial Lipoatrophy (AIFL) because the filler treatment Sculptra™ has been added to the list of medically necessary prosthetic devices by the Prosthetic and Sensory AIDS Service (PSAS). The HIV/HCV Public Health Pathogens Program will provide VHA-approved educational information to HIV providers and primary care providers who treat HIV patients, about the use of fillers to treat lipoatrophy in HIV patients.

3. All inquiries concerning this action should be addressed to the HIV/HCV Public Health Pathogens Program (10P4I, previously 10P3B) at 415-264-0878.

4. This VHA Notice will be archived as of September 30, 2017. However, the rescission information will remain in effect.

David J. Shulkin, M.D.
Under Secretary for Health

DISTRIBUTION: Emailed to the VHA Publications Distribution List on 9/30/16.